Inactive Instrument

Highlights Capricor Therapeutics Inc Nasdaq

Equities

US14070B1017

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	Apr. 24	MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	Apr. 24	CI
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference	Mar. 06	CI
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M	Feb. 29	MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise	Feb. 27	MT
Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization	Feb. 20	CI
Capricor Therapeutics Shares Rise 7% After Collaboration for Covid-19 Vaccine	Jan. 24	DJ
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2	Jan. 24	CI
Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis	Dec. 11	CI
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Reports Q3 Revenue $6.2M, vs. Street Est of $3.17M	Nov. 14	MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy	23-09-29	CI
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q2 Revenue $3.9M, vs. Street Est of $1.6M	23-08-07	MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Capricor Therapeutics Announces Appointment of Philip J. Gotwals to Its Board of Directors	23-07-24	CI
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy	23-06-30	CI
Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy	23-06-07	CI
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $3M	23-05-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Capricor Therapeutics Inc Nasdaq

Equities

US14070B1017

Highlights

Filters